Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12

Arlene Lobo, Arabi Naso, Kristopher Arheart, Warren D. Kruger, Tariq Abou-Ghazala, Fadi Alsous, Maher Nahlawi, Anjan Gupta, Ali Moustapha, Frederick Van Lente, Donald W. Jacobsen, Killian Robinson

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

An increased plasma homocysteine concentration is a risk factor for atherosclerosis. Folic acid lowers homocysteine but the optimal dose in patients with coronary artery disease (CAD) is unclear. This placebo- controlled, single-blind, dose-ranging study evaluates the effect of low- dose folic acid on homocysteine levels in 95 patients aged 61 ± 11 years (mean ± SD) with documented CAD. Patients in each group were given either placebo or 1 of 3 daily supplements of folic acid (400 μg, 1 mg, or 5 mg) for 3 months. Each active treatment arm also received 500 μg vitamin B12 and 12.5 mg vitamin B6. Total plasma homocysteine levels were measured after 30 and 90 days. Folic acid 400 μg reduced homocysteine levels from 13.8 ± 8.8 to 9.6 ± 2.0 μmol/L at 90 days (p = 0.001). On 1- and 5-mg folic acid, levels decreased from 13.0 ± 6.4 to 9.8 ± 4.0 μmol/L (p = 0.001) and from 14.8 ± 6.9 to 9.7 ± 3.3 μmol/L (p <0.001), respectively. The decrease was similar in all treatment groups. There was no significant change with placebo. Although the sample size is small, these findings suggest that daily administration of 400 μg/day folic acid combined with vitamin B12 and vitamin B6 may be equivalent to higher doses in reducing homocysteine levels in patients with CAD.

Original languageEnglish
Pages (from-to)821-825
Number of pages5
JournalAmerican Journal of Cardiology
Volume83
Issue number6
DOIs
StatePublished - Mar 15 1999
Externally publishedYes

Fingerprint

Vitamin B 6
Homocysteine
Vitamin B 12
Folic Acid
Coronary Artery Disease
Placebos
Sample Size
Atherosclerosis
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. / Lobo, Arlene; Naso, Arabi; Arheart, Kristopher; Kruger, Warren D.; Abou-Ghazala, Tariq; Alsous, Fadi; Nahlawi, Maher; Gupta, Anjan; Moustapha, Ali; Van Lente, Frederick; Jacobsen, Donald W.; Robinson, Killian.

In: American Journal of Cardiology, Vol. 83, No. 6, 15.03.1999, p. 821-825.

Research output: Contribution to journalArticle

Lobo, A, Naso, A, Arheart, K, Kruger, WD, Abou-Ghazala, T, Alsous, F, Nahlawi, M, Gupta, A, Moustapha, A, Van Lente, F, Jacobsen, DW & Robinson, K 1999, 'Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12', American Journal of Cardiology, vol. 83, no. 6, pp. 821-825. https://doi.org/10.1016/S0002-9149(98)01041-8
Lobo, Arlene ; Naso, Arabi ; Arheart, Kristopher ; Kruger, Warren D. ; Abou-Ghazala, Tariq ; Alsous, Fadi ; Nahlawi, Maher ; Gupta, Anjan ; Moustapha, Ali ; Van Lente, Frederick ; Jacobsen, Donald W. ; Robinson, Killian. / Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. In: American Journal of Cardiology. 1999 ; Vol. 83, No. 6. pp. 821-825.
@article{f64d1d78f5df48c1a66e396641feeaaa,
title = "Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12",
abstract = "An increased plasma homocysteine concentration is a risk factor for atherosclerosis. Folic acid lowers homocysteine but the optimal dose in patients with coronary artery disease (CAD) is unclear. This placebo- controlled, single-blind, dose-ranging study evaluates the effect of low- dose folic acid on homocysteine levels in 95 patients aged 61 ± 11 years (mean ± SD) with documented CAD. Patients in each group were given either placebo or 1 of 3 daily supplements of folic acid (400 μg, 1 mg, or 5 mg) for 3 months. Each active treatment arm also received 500 μg vitamin B12 and 12.5 mg vitamin B6. Total plasma homocysteine levels were measured after 30 and 90 days. Folic acid 400 μg reduced homocysteine levels from 13.8 ± 8.8 to 9.6 ± 2.0 μmol/L at 90 days (p = 0.001). On 1- and 5-mg folic acid, levels decreased from 13.0 ± 6.4 to 9.8 ± 4.0 μmol/L (p = 0.001) and from 14.8 ± 6.9 to 9.7 ± 3.3 μmol/L (p <0.001), respectively. The decrease was similar in all treatment groups. There was no significant change with placebo. Although the sample size is small, these findings suggest that daily administration of 400 μg/day folic acid combined with vitamin B12 and vitamin B6 may be equivalent to higher doses in reducing homocysteine levels in patients with CAD.",
author = "Arlene Lobo and Arabi Naso and Kristopher Arheart and Kruger, {Warren D.} and Tariq Abou-Ghazala and Fadi Alsous and Maher Nahlawi and Anjan Gupta and Ali Moustapha and {Van Lente}, Frederick and Jacobsen, {Donald W.} and Killian Robinson",
year = "1999",
month = "3",
day = "15",
doi = "10.1016/S0002-9149(98)01041-8",
language = "English",
volume = "83",
pages = "821--825",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12

AU - Lobo, Arlene

AU - Naso, Arabi

AU - Arheart, Kristopher

AU - Kruger, Warren D.

AU - Abou-Ghazala, Tariq

AU - Alsous, Fadi

AU - Nahlawi, Maher

AU - Gupta, Anjan

AU - Moustapha, Ali

AU - Van Lente, Frederick

AU - Jacobsen, Donald W.

AU - Robinson, Killian

PY - 1999/3/15

Y1 - 1999/3/15

N2 - An increased plasma homocysteine concentration is a risk factor for atherosclerosis. Folic acid lowers homocysteine but the optimal dose in patients with coronary artery disease (CAD) is unclear. This placebo- controlled, single-blind, dose-ranging study evaluates the effect of low- dose folic acid on homocysteine levels in 95 patients aged 61 ± 11 years (mean ± SD) with documented CAD. Patients in each group were given either placebo or 1 of 3 daily supplements of folic acid (400 μg, 1 mg, or 5 mg) for 3 months. Each active treatment arm also received 500 μg vitamin B12 and 12.5 mg vitamin B6. Total plasma homocysteine levels were measured after 30 and 90 days. Folic acid 400 μg reduced homocysteine levels from 13.8 ± 8.8 to 9.6 ± 2.0 μmol/L at 90 days (p = 0.001). On 1- and 5-mg folic acid, levels decreased from 13.0 ± 6.4 to 9.8 ± 4.0 μmol/L (p = 0.001) and from 14.8 ± 6.9 to 9.7 ± 3.3 μmol/L (p <0.001), respectively. The decrease was similar in all treatment groups. There was no significant change with placebo. Although the sample size is small, these findings suggest that daily administration of 400 μg/day folic acid combined with vitamin B12 and vitamin B6 may be equivalent to higher doses in reducing homocysteine levels in patients with CAD.

AB - An increased plasma homocysteine concentration is a risk factor for atherosclerosis. Folic acid lowers homocysteine but the optimal dose in patients with coronary artery disease (CAD) is unclear. This placebo- controlled, single-blind, dose-ranging study evaluates the effect of low- dose folic acid on homocysteine levels in 95 patients aged 61 ± 11 years (mean ± SD) with documented CAD. Patients in each group were given either placebo or 1 of 3 daily supplements of folic acid (400 μg, 1 mg, or 5 mg) for 3 months. Each active treatment arm also received 500 μg vitamin B12 and 12.5 mg vitamin B6. Total plasma homocysteine levels were measured after 30 and 90 days. Folic acid 400 μg reduced homocysteine levels from 13.8 ± 8.8 to 9.6 ± 2.0 μmol/L at 90 days (p = 0.001). On 1- and 5-mg folic acid, levels decreased from 13.0 ± 6.4 to 9.8 ± 4.0 μmol/L (p = 0.001) and from 14.8 ± 6.9 to 9.7 ± 3.3 μmol/L (p <0.001), respectively. The decrease was similar in all treatment groups. There was no significant change with placebo. Although the sample size is small, these findings suggest that daily administration of 400 μg/day folic acid combined with vitamin B12 and vitamin B6 may be equivalent to higher doses in reducing homocysteine levels in patients with CAD.

UR - http://www.scopus.com/inward/record.url?scp=0033039304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033039304&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(98)01041-8

DO - 10.1016/S0002-9149(98)01041-8

M3 - Article

VL - 83

SP - 821

EP - 825

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -